Measures · D05 in 2023 · Part D · DD3 Member Experience with the Drug Plan
Rating of Drug Plan
Drug PlanMember ExperienceSource: CAHPS
- What it measures
- Percent of the best possible score the plan earned from members who rated the prescription drug plan.
- How it's calculated
- This case-mix adjusted measure is used to assess members' overall view of their prescription drug plan. The Consumer Assessment of Healthcare Providers and Systems (CAHPS) score uses the mean of the distribution of responses converted to a scale from 0 to 100. The score shown is the percentage of the best possible score each contract earned.
- Data source
- CAHPS CAHPS Survey Questions (question numbers vary depending on survey type): • Using any number from 0 to 10, where 0 is the worst prescription drug plan possible and 10 is the best prescription drug plan possible, what number would you use to rate your prescription drug plan?
- Measurement period
- 03/2022 – 06/2022
- Better when
- Higher
- Weight
- 4 (Patients’ Experience and Complaints Measure)
- Star assignment
- Relative Distribution and Significance Testing
- Case-mix adjusted
- Yes
- In improvement measure
- Yes
- Used in CAI
- No
- Notes
- CAHPS Survey results were sent to each contract's Medicare Compliance Officer in August 2022. These reports provide further explanation of the CAHPS scoring methodology and provide detailed information on why a specific rating was assigned.
- Disaster policy
- Higher measure star (2022-2023) for contracts with 25% or more enrolled affected by 2021 disasters.
From the 2023 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 86 | 86 | 0 |
| 4★ | MA-PD | 87 | 87 | 0 |
| 5★ | MA-PD | 89 | 89 | 0 |
| 2★ | PDP | 82 | 82 | 0 |
| 3★ | PDP | 83 | 83 | 0 |
| 4★ | PDP | 86 | 86 | 0 |
| 5★ | PDP | 88 | 88 | 0 |
2023 star distribution
Not rated: Plan too small to be measured (159); Plan too new to be measured (130); No data available (28); Plan not required to report measure (6); Not enough data available (2)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 to < 89 | >= 89 |
| 2027 | PDP | < 82 | >= 82 to < 83 | >= 83 to < 86 | >= 86 to < 88 | >= 88 |
| 2026 | MA-PD | < 85 | >= 85 to < 86 | >= 86 to < 88 | >= 88 to < 89 | >= 89 |
| 2026 | PDP | < 82 | >= 82 to < 83 | >= 83 to < 86 | >= 86 to < 88 | >= 88 |
| 2025 | MA-PD | < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 to < 89 | >= 89 |
| 2025 | PDP | < 79 | >= 79 to < 82 | >= 82 to < 85 | >= 85 to < 87 | >= 87 |
| 2024 | MA-PD | < 84 | >= 84 to < 85 | >= 85 to < 87 | >= 87 to < 89 | >= 89 |
| 2024 | PDP | < 80 | >= 80 to < 81 | >= 81 to < 83 | >= 83 to < 87 | >= 87 |
| 2023 | MA-PD | < 83 | >= 83 to < 85 | >= 85 to < 87 | >= 87 to < 88 | >= 88 |
| 2023 | PDP | < 79 | >= 79 to < 80 | >= 80 to < 83 | >= 83 to < 87 | >= 87 |
| 2022 | MA-PD | < 84 | >= 84 to < 85 | >= 85 to < 87 | >= 87 to < 88 | >= 88 |
| 2022 | PDP | < 80 | >= 80 to < 82 | >= 82 to < 84 | >= 84 to < 87 | >= 87 |
| 2021 | MA-PD | < 83 | >= 83 to < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 |
| 2021 | PDP | < 80 | >= 80 to < 81 | >= 81 to < 83 | >= 83 to < 87 | >= 87 |
| 2020 | MA-PD | < 83 | ? 83 to < 84 | ? 84 to < 86 | ? 86 to < 87 | ? 87 |
| 2020 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 83 | ? 83 to < 87 | ? 87 |
| 2019 | MA-PD | < 82 | ? 82 to < 83 | ? 83 to < 85 | ? 85 to < 87 | ? 87 |
| 2019 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 84 | ? 84 to < 86 | ? 86 |
| 2018 | MA-PD | < 81 | ? 81 to < 83 | ? 83 to < 85 | ? 85 to < 86 | ? 86 |
| 2018 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 83 | ? 83 to < 87 | ? 87 |
| 2017 | MA-PD | < 80 | ? 80 to < 82 | ? 82 to < 84 | ? 84 to < 86 | ? 86 |
| 2017 | PDP | < 79 | ? 79 to < 80 | ? 80 to < 83 | ? 83 to < 86 | ? 86 |
| 2016 | MA-PD | < 80 | ? 80 to < 82 | ? 82 to < 84 | ? 84 to < 86 | ? 86 |
| 2016 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 82 | ? 82 to < 86 | ? 86 |
| 2015 | MA-PD | < 82% | ? 82% to < 83% | ? 83% to < 84% | ? 84% to < 87% | ? 87% |
| 2015 | PDP | < 80% | ? 80% to < 81% | * | ? 81% to < 86% | ? 86% |
Lowest-scoring contracts, 2023
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S2874 Humana | Humana Inc. | — | 73 | 1 | −1 | 10 | 0% |
| H2836 Anthem Blue Cross and Blue Shield | Elevance Health, Inc. | 2,426 | 77 | 1 | — | 10 | 0% |
| H6067 CareFirst BlueCross BlueShield Medicare Advantage | CareFirst, Inc. | — | 78 | 1 | — | 9 | 0% |
| H8552 Anthem Blue Cross Life and Health Insurance Company | Elevance Health, Inc. | 1,065 | 79 | 1 | −2 | 8 | 0% |
| H5991 EmblemHealth | EmblemHealth, Inc. | 2,285 | 80 | 1 | 0 | 7 | 1% |
| H3152 Aetna Medicare | CVS Health Corporation | 30,674 | 80 | 1 | −1 | 7 | 1% |
| H4213 Arkansas Blue Medicare | USAble Mutual Insurance Company | 2,258 | 80 | 1 | 0 | 7 | 1% |
| H2134 Wellcare by Allwell | Centene Corporation | — | 81 | 1 | — | 6 | 1% |
| H1732 ANTHEM BLUE CROSS AND BLUE SHIELD HP | Elevance Health, Inc. | — | 81 | 1 | — | 6 | 1% |
| H8432 Anthem Blue Cross and Blue Shield HP | Elevance Health, Inc. | 43,447 | 81 | 1 | 0 | 6 | 1% |
| H9431 Aetna Medicare | CVS Health Corporation | 666 | 81 | 1 | 0 | 6 | 1% |
| H3047 Wellcare | Centene Corporation | — | 81 | 1 | — | 6 | 1% |
| H5435 UnitedHealthcare | UnitedHealth Group, Inc. | 1,420 | 81 | 1 | 0 | 6 | 1% |
| H3307 UnitedHealthcare | UnitedHealth Group, Inc. | — | 81 | 1 | 0 | 6 | 1% |
| H4829 UnitedHealthcare | UnitedHealth Group, Inc. | — | 81 | 1 | — | 6 | 1% |
| S3375 BlueCross BlueShield: Empire, Excellus, WNY & NENY | Elevance Health, Inc. | — | 75 | 1 | — | 8 | 2% |
| S8182 Amerigroup | Elevance Health, Inc. | — | 75 | 1 | 0 | 8 | 2% |
| H1914 Wellcare | Centene Corporation | 10,826 | 82 | 1 | 0 | 5 | 3% |
| H1894 Wellpoint | Elevance Health, Inc. | 2,322 | 82 | 2 | +1 | 5 | 3% |
| H4868 Wellcare | Centene Corporation | 39,248 | 82 | 2 | 0 | 5 | 3% |
| R3332 Florida Blue | Guidewell Mutual Holding Corporation | — | 82 | 1 | −1 | 5 | 3% |
| H1659 UnitedHealthcare | UnitedHealth Group, Inc. | 2,487 | 82 | 1 | −2 | 5 | 3% |
| H5989 Healthfirst Medicare Plan | Healthfirst, Inc. | 12,756 | 82 | 2 | — | 5 | 3% |
| H3471 Health Alliance Northwest | The Carle Foundation | — | 82 | 1 | −2 | 5 | 3% |
| H3748 Aetna Medicare | CVS Health Corporation | 4,321 | 82 | 1 | 0 | 5 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D05 | Rating of Drug Plan | 03/2026 – 06/2026 | 2 | CAHPS |
| 2026 | D05 | Rating of Drug Plan | 03/2025 – 05/2025 | 2 | CAHPS |
| 2025 | D05 | Rating of Drug Plan | 03/2024 – 06/2024 | 4 | CAHPS |
| 2024 | D05 | Rating of Drug Plan | 03/2023 – 06/2023 | 4 | CAHPS |
| 2023 | D05 | Rating of Drug Plan | 03/2022 – 06/2022 | 4 | CAHPS |
| 2022 | D05 | Rating of Drug Plan | 03/2021 – 05/2021 | 2 | CAHPS |
| 2021 | D07 | Rating of Drug Plan | 03/2019 – 05/2019 | 2 | CAHPS |
| 2020 | D07 | Rating of Drug Plan | 03/2019 – 05/2019 | 1.5 | CAHPS |
| 2019 | D07 | Rating of Drug Plan | 03/2018 – 06/2018 | 1.5 | CAHPS |
| 2018 | D08 | Rating of Drug Plan | 03/2017 – 06/2017 | 1.5 | CAHPS |
| 2017 | D08 | Rating of Drug Plan | 02/2016 – 08/2016 | 1.5 | CAHPS |
| 2016 | D08 | Rating of Drug Plan | 02/15/2015 - 05/31/2015 | 1.5 | CAHPS |
| 2015 | D06 | Rating of Drug Plan | 02/15/2014 - 05/31/2014 | 1.5 | CAHPS |